The IGF2-INS-TH genomic region has been implicated in various common disorders including the metabolic syndrome, type 2 diabetes and coronary heart disease (CHD).
Introduction
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and body mass. This literature is summarized in Table 2 . However, although linkage disequilibrium across this gene cluster has been recognized previously, no study has yet attempted to examine markers across the whole cluster in a systematic way in relation to a set of cardiovascular risk traits. In this study, we have undertaken an integrated haplotypic analysis in 2743 Caucasian males (51-62 years) comprising the UK Northwick Park Heart Study II, a UK-wide cohort study of cardiovascular risk traits. Table 3 shows the association of the five commonest IGF2 11-SNP haplotypes in relation to the TH01 and INS VNTR alleles. It can be seen that haplotypes that we have designated A, C, D and E are strongly associated with alleles 6, 9, 7 and 9.3, respectively. Consideration of TH01 and IGF2 ApaI allows a nearly complete tagging of all the information given by the combination of TH01 and the 11 IGF2 SNPs: haplotypes 6-1, 9-2, 7-1 and 9.3-2 tag haplotypes A, C, D and E respectively and haplotype 9.3-1 tags mainly haplotype B and haplotype A to a minor extent. The information given by TH01 and the 11 IGF2 SNPs can thus be reduced to a combination of the microsatellite and one single IGF2 SNP (ApaI). Addition of the INS HphI site permits distinction between classI/classIII alleles at the INS VNTR locus (8) . IGF2 ApaI-INS HphI-TH01 haplotypes thus tag the information given by 14 polymorphisms of this region. This both increased the number of individuals available with complete data (from 282 to 2061), reduced the uncertainties of indirect haplotype deduction and reduced the number of rare or artefactual haplotypes, total number then being 21 compared with 203. The latter problem would have been a major issue for haplotype regression analyses (9). Consistent with approaches to reduce risk of false positive findings related to low-frequency haplotypes (10), we considered the 10 haplotypes with a frequency higher than 3%, representing 89% of all haplotypes (Table 4 ). Table 5 shows the results obtained by the Haplotype Trend Regression (HTR) program and Table 6 shows the P values computed by haplo.score and the mean for each phenotype computed from the haplotypes deduced by Phase. A complete agreement was obtained by all the approaches used. Six out of the ten commonest haplotypes at the IGF2-INS-TH region show significant association with at least one of the phenotypes. In total, 12 significant associations were found and two haplotypes showed trend (0.10 ≤ P < 0.05) in both HTR and haplo.score analyses (Tables 5 and 6 ). These results are also in agreement with the empirical P-values obtained by simulation using haplo.score (unpublished data). The mean values of each phenotype for haplotypes deduced via HTR or Phase are qualitatively similar (Tables 5 and 6 ). The results obtained from the cladistic-based association analysis performed by the program Evolutionary-based 10 percentage fat and LBM , and approximately 20% for plasma TG, whereas considerably smaller differences (2 -12%) could be detected with a 90% power for the more frequent haplotypes. The total number of haplotypes observed for fat mass, percentage fat and LBM was 1180, and 4061 for plasma TG. The lowest range of observed percentage of detectable differences for five haplotypes representative of our haplotype frequencies (*1, *2, *3, *5 and *10) was for height (0.5 -1%), followed by weight, systolic BP, diastolic BP (1.5 -3.5%), LBM (2 -10%), percentage fat (6 -12%), fat mass (7 -13%) and plasma TG (10 -22%).
Results
Tagging of the haplotypic information in the IGF2-INS-TH region
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Comparisons of the results obtained by different testing approaches
Discussion
This study represents the first detailed description both of the IGF2 haplotypes and of the haplotypic effects of the IGF2-INS-TH region on a spectrum of cardiovascular risk traits. The study was undertaken in a cohort of 2743 middle-aged Caucasian males from a UK multicentre study of cardiovascular risk. Haplotypes were identified which may be contributors to combinations of fat mass, plasma TG level and raised BP, while others may influence anthropometric traits. Comparison of these haplotypes permits an integrating hypothesis and, in conjunction with identification of a marker set for tagging haplotypes, opens the way to more thorough studies of this 'polygene' in cardiovascular risk traits and coronary case studies.
Haplotype IGF2-INS-TH*4 is associated with significantly higher fat mass and percentage fat, and with significantly higher diastolic BP: the means for systolic BP and plasma TG are also respectively the highest and second highest for any haplotype, although not significant. Interestingly, similar magnitudes of effects were observed for (Table   3 ). In general, previous literature concerned with case studies in coronary disease, type alleles have been associated with lower insulin secretion and irregular insulin pulsatility in class III/III-positive individuals (Table 2) , and with lower INS mRNA transcript levels in pancreatic beta cells (Table 1) . However, plasma TG has remained essentially uninvestigated for INS VNTR, IGF2 or TH genotype effects, although this is an obvious hypothesis for INS VNTR. There is a single early case study of type 2 diabetics which showed that long alleles were more prevalent in hypertriglyceridemic than in normotriglyceridemic type 2 diabetics (11) which accord with our findings in a population-based sample. The higher diastolic BP observed for haplotype *4 could be related with the reported insulin-mediated vasodilatation via nitric oxide release (Table 1) ; class III alleles at *4 would lead to a reduced availability of insulin and subsequent reduction in the expression of endothelial nitric oxide synthase. This would result in a diminished vasodilatation and increased BP. Other factors may be implicated in the effect observed, given that haplotype *6, also including class III alleles, does not show higher BP. In a case study, Sharma et al. (20) implicated TH01 allele 9.3 in hypertension; it is possible that this could represent the effect of the *4 haplotype observed here although TH01 allele 9.3 is also found in haplotypes *3, *6 and *10. By contrast, the other four TH01 alleles display rather more restricted distributions on IGF2 and IGF2-INS haplotypes. Thus, in general, these observations in this cohort study identify haplotypes consistent with case studies of INS VNTR and TH01 alleles.
IGF2-INS-TH
Haplotype *8 contains TH01 allele 8 and therefore (12) represents the INS VNTR lineage/class IIIB which is recognised to be the very protective haplotype (VPH) in type 1 diabetes. By contrast, both *4 and *6 haplotypes contain TH01 allele 9.3 and they represent the INS VNTR lineage/class IIIA which is known to be a pure lineage and is the protective haplotype (PH) in type 1 diabetes (12). However, here we show that the *6 haplotype represents a different IGF2 haplotype (E) which is identical with IGF2 13 haplotype C and *5 haplotype at its 3' end. It is possible therefore that the INS VNTR 'class III effects' observed for haplotypes *4 and *8 are modulated by the different IGF2 haplotype evident for *6, a haplotype which in fact has features in common with the weight-lowering haplotype *5.
We have previously reported evidence of associations of markers in IGF2, INS, and TH to low weight and BMI (13-15). However, for the first time here, it can be seen definitively that one unique haplotype, *5, contains these markers and shows a highly significant association with low weight and low BMI. Additionally, for the first time, we show that this low BMI reflects a significantly low LBM and also low fat mass.
Power calculations show that the study had considerably more power to determine LBM than fat mass effects. LBM represents 75% of body mass and fat mass represents 25% of body mass, the latter showing greater variance, whereas there is a 1.33kg effect for In addition, the congruence between the different approaches used to test for significance supports the validity of the associations found. Replication of the results found in this work in an independent sample would provide stronger evidence of the 16 presence of a quantitative trait locus for cardiovascular traits in the IGF2-INS-TH gene cluster. However, the effect measurements in our study are mutually consistent with an increasing body of literature that suggests that this region may be important in obesity, metabolic disease and cardiovascular disease. Table 7 summarises existent genotypic associations -some but not all can be integrated but several need further data at the haplotypic level. The weight-lowering haplotype *5 contains the INS VNTR class IC+ alleles most prominently linked and associated with type 1 diabetes, and it also contains the TH01 allele 9 overrepresented in normotensive controls in a hypertension case study (19) . INS VNTR class III associations with type 2 diabetes, PCOS and high TG levels in diabetics must reflect some or all of haplotypes *4, *6 and *8, of which *4 and *8 appear to associate with raised fat mass and diastolic BP and *6 with raised TG level, but further case studies will be needed to determine whether the IGF2 haplotype of *6 modulates INS VNTR class III effects. However, observations in hypertension and longevity relating to TH01 allele 9.3 are difficult to interpret because this allele is found in association with a variety of IGF2 and INS haplotypes.
The potential significance of haplotype *4 (10.2% of alleles) to cardiovascular risk is not trivial. A 1.29mmHg higher diastolic BP equates with about a 6-8% increment in stroke risk and a 4-5% increment in CHD risk (20). Comparable estimations can be made for the 10% fat mass increment and for the 10% higher plasma TG of haplotype *6 in relation to the metabolic syndrome. The weight-lowering effect of *5 (1 BMI unit) represents about a 10% increase in the rate of coronary events (21). This systematic description identifies tagging markers and specific haplotypes (particularly *4 for risk and *5 for protection), permitting deeper epidemiological and functional investigation of IGF2-INS-TH as a cardiovascular risk polygene.
Materials and Methods
Study sample
The Northwick Park Heart Study II (NPHSII) (22) was studied as a marker of the TH gene region.
Genotyping
Experimental conditions for the genotyping of polymorphisms are as previously described (14,15). In brief, the eleven SNPs at IGF2 and HphI were typed by PCR adopting the Amplification Refractory Mutation System (ARMS) (24) or by digesting each amplification product by the corresponding restriction enzyme. The TH microsatellite TH01 and the INS minisatellite were amplified with primers and PCR conditions previously described (25-27). The amplification products (VNTR, microsatellite and SNP assays) in all cases were resolved by Microplate Array Diagonal
Gel Electrophoresis (MADGE) as previously described (28-32). The distributions of the haplotypes significantly associated with each trait were tested for normality in SPSS using the Kolmogorov-Smirnov goodness-of-fit test (39).
Statistical analyses
Retrospective power analyses were also conducted for the detected associations and computed the percentage of detectable differences for each trait for a given power of 90%. Power calculations were performed as previously described (40) Increased activation of the haemostatic system in men at high risk of fatal coronary heart disease. 
